Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > NSCLC and GBM indications

<< Previous

Bullboard Posts

Next >>

Comment by ScienceFirston Dec 16, 2022 10:57am

251 Views

Post# 35175721

RE:NSCLC and GBM indications

The real signal concerning these 2 indications will be when we'll hear about MDAB nomination with specialists in these 2 fields of expertise.

It's impossible that TLT moves ahead without such nominations. It's a question of credibility and industry requirements.

UHN specialists that once collaborated in these fields (Drs Yasufuku, Cypel, Zadeh, etc ...) are all possible choices as they are all aware of our technology. UHN could then consolidate its credibility in the PDT/PDC arena.

UHN:

No one in Canada is doing more for brain health than us

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario